Boehringer Ingelheim’s HIV Therapy Aptivus Gets Full FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Protease inhibitor received accelerated approval in June 2005, but FDA requested additional post-marketing trials.